Muhammad Jan, MD
Interventional Cardiology · Milwaukee, WINPI 1912956178
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (47.0%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. ZOLL Circulation Inc accounts for 67.0% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $5,143, more than ten times the $158 reported in 2019.
Across 38 payments — averaging $288.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Circulation Inc$7K
- Abbott$1K
- Boston Scientific$1K
- Medtronic$420
- Edwards Lifesciences$269
- AstraZeneca$198
- plus $477 from 6 others
Across 14 payments — averaging $3102.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Lexicon Pharmaceuticals, Inc.$42K
- Heartflow, Inc.$1K
- Amgen$803
What the payments were for
- Consulting fees$2,00018%
- Speaking & faculty fees$2,00018%
- Travel & lodging$5,15347%
- Food & beverage$1,57714%
- Education$2302%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Circulation Inc | 6 | $7,342 |
| Abbott | 9 | $1,214 |
| Boston Scientific | 7 | $1,041 |
| Medtronic | 5 | $420 |
| Edwards Lifesciences | 2 | $269 |
| AstraZeneca | 2 | $198 |
| Cvrx, Inc. | 1 | $148 |
| Terumo Medical Corporation | 1 | $117 |
| Shockwave Medical, Inc | 1 | $111 |
| Akcea Therapeutics, Inc. | 1 | $59 |
| Novo Nordisk | 1 | $32 |
| Cardiovascular Systems Inc. | 2 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TherOx DS2 Console$7,342
- Catheter$7,342
- Downstream Cartridge$7,342
- VersaCross Access Solution$893
- DRAGONFLY OPSTAR$865
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$269
- ONYX FRONTIER$171
- MitraClip$170
- Barostim Neo System$148
- CoreValve Evolut$137
- R2P MISAGO$117
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$111
- WATCHMAN Access System$104
How this compares
$10,961 in reported general payments places this provider in the 70th percentile of 118 interventional cardiology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 775 | $830,597 |
| EntrestoSacubitril/Valsartan | 714 | $826,510 |
| JardianceEmpagliflozin | 601 | $718,460 |
| VyndamaxTafamidis | 23 | $710,029 |
| Repatha SureclickEvolocumab | 373 | $227,152 |
| BrilintaTicagrelor | 231 | $213,066 |
| XareltoRivaroxaban | 175 | $206,103 |
| VerquvoVericiguat | 75 | $101,325 |
| CorlanorIvabradine Hcl | 85 | $87,358 |
| VascepaIcosapent Ethyl | 64 | $52,482 |
| FarxigaDapagliflozin Propanediol | 32 | $37,313 |
| Praluent PenAlirocumab | 60 | $32,539 |
| Repatha SyringeEvolocumab | 45 | $30,725 |
| MounjaroTirzepatide | 28 | $30,079 |
| Metoprolol Succinate | 1,449 | $22,105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBrilinta, Farxiga | $198 | $250,379263 claims |
| Novo NordiskWegovy | $32 | $15,03911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 118 interventional cardiology providers in Wisconsin.
Other interventional cardiology in Milwaukee
- Michael SalingerMilwaukee$216K
- Tanvir BajwaMilwaukee$106K
- Suhail AllaqabandMilwaukee$88K
- Saif AnwaruddinMilwaukee$80K
- Iyad AzzamMilwaukee$60K
- Montoya TaylorMilwaukee$48K
- Mina IskanderMilwaukee$41K
- Anna LarosaMilwaukee$38K
- Louie KostopoulosMilwaukee$26K
- Daniel JohnsrudMilwaukee$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.